The Law and Ethics of Switching from Biologic to Biosimilar in Canada
Open Access
- 3 January 2020
- journal article
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 3 (5) , 228-233
Abstract
Governments and financial institutions in several jurisdictions are planning or implementing nonmedical/‘forced’ switches by cutting drug coverage for reference biologics and funding only less expensive biosimilars. Switches raise numerous ethical and legal challenges, as the drugs are framed as not being identical and, despite strong evidence for noninferiority of some biosimilars, there is controversy over whether switching can sometimes lead to adverse events. Canadian law generally requires physicians to give precedence to their patients’ best interests over social interests such as cost containment. The primacy of patients’ interests is also clearly reflected in professional policies and codes of ethics. Moreover, physicians are obligated to disclose everything a reasonable person in the patient’s position would want to know when obtaining informed consent for treatment, including addressing not only scientific information but also relevant social controversy about nonmedical switches. Under Canadian law, physicians may be obligated to tell patients about the ability to access unfunded biologics, even if patients lack the resources to obtain them. In sum, while there is no inherent right to funding for reference biologics in Canada, physicians in some circumstances may have a legal obligation as fiduciaries to advocate on behalf of patients to remain on a reference biologic. At a minimum, the controversy surrounding switching will necessitate, as part of the consent process, a robust and thorough disclosure of relevant risks, benefits and reasonable alternatives.Keywords
Funding Information
- Crohn's and Colitis Canada
This publication has 33 references indexed in Scilit:
- Controversies with Kalydeco: Newspaper coverage in Canada and the United States of the cystic fibrosis “wonder drug”Journal of Cystic Fibrosis, 2016
- Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public healthBiologicals, 2016
- Measuring online social bubblesPeerJ Computer Science, 2015
- Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational dataExpert Opinion on Biological Therapy, 2015
- Biosimilars in inflammatory bowel diseaseCurrent Opinion in Gastroenterology, 2015
- Medical malpractice, defensive medicine and role of the “media” in ItalyMultidisciplinary Respiratory Medicine, 2015
- ECCO 2013 survey highlights lack of confidence in biosimilarsGenerics and Biosimilars Initiative Journal, 2014
- Angelina Jolie’s faulty gene: newspaper coverage of a celebrity’s preventive bilateral mastectomy in Canada, the United States, and the United KingdomGenetics in Medicine, 2014
- A New Dimension of Health Care: Systematic Review of the Uses, Benefits, and Limitations of Social Media for Health CommunicationJournal of Medical Internet Research, 2013
- Coping with obligations towards patient and society: an empirical study of attitudes and practice among Norwegian physicians.Journal of Medical Ethics, 1995